David Marin


Affiliation: Imperial College
Country: UK


  1. Marin D, Khorashad J, Foroni L, Milojkovic D, Szydlo R, Reid A, et al. Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?. Br J Haematol. 2009;145:373-5 pubmed publisher
    ..05%; increases that never exceeded 0.05% had no predictive value. The finding of a kinase domain mutation in a patient in CCyR, though rare, also predicted for loss of CCyR. ..
  2. Marin D, Bazeos A, Mahon F, Eliasson L, Milojkovic D, Bua M, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28:2381-8 pubmed publisher
    ..66; P = .006). In patients with CML treated with imatinib for some years, poor adherence may be the predominant reason for inability to obtain adequate molecular responses. ..
  3. Marin D. Management of the new patient with CML in chronic phase. Curr Hematol Malig Rep. 2013;8:37-42 pubmed publisher
    ..In this paper we analyze the pros and cons of the various alternatives to imatinib and try to give some advice on the management of the newly diagnosed patient. ..